IND
Xtrackers Nifty 500 India ETF
stock NASDAQ ETF

The IND money part is not that complicated
You can start with smaller amounts depending on your income and risk appetite
And the ITR part IND money generates clear reports for capital gains so i don't think it'll be that complicated
iND money takes an exchange rate 1 usd = 100 INR with GST which is ok I feel considering our currencies exchange rate

IND Money
Not a great app, not much privacy - they have access to your messages and they track your bank transactions.
Try some other apps - but there might be minor charges. Like, vested.

Been following Cue Biopharma for a bit and the last few weeks have been unusually busy for a small clinical stage company. New CEO, new lead asset, fresh capital raise, conference presentation announced. Trying to piece together whether this is a genuine reset or just noise.
The financial picture first. Q1 revenue came in at $5.7 million versus $0.4 million in the same quarter last year. That sounds like a huge jump until you read the fine print. The entire amount came from a collaboration milestone payment tied to the Boehringer Ingelheim agreement. It is not product revenue and it is not recurring by nature. The prior year figure came from a different collaboration that was actually terminated in March 2025. So the year over year comparison is essentially two different one-time events stacked against each other.
Net loss narrowed to $5.2 million from $12.3 million a year ago. R&D spending dropped from $8.5 million to $6.9 million, mostly because the previous lead program wound down. G&A stayed flat at $4.2 million.
Cash was $16.4 million at March 31 which on its own looks thin. But subsequent to quarter end the company closed a $30 million private placement and received a $7.5 million milestone from Boehringer Ingelheim. Pro forma that is roughly $54 million before expenses. That is a meaningfully different runway than the balance sheet date figure suggests.
On the pipeline side the company has essentially pivoted. The old oncology direction is gone. The new lead asset is CUE-221, an anti-IgE antibody licensed from Ascendant Health Sciences, currently in Phase 2 for allergic diseases. The decision to advance into a global Phase 2b food allergy trial depends on results from a China Phase 2 study that Ascendant is running, expected in the second half of 2026. Cue does not control that study.
The second asset is CUE-401, a bifunctional cytokine candidate for autoimmune disease. IND submission expected in the second half of 2026, Phase 1 first in human study by year end.
The new CEO Shao-Lee Lin was granted options on 655,074 shares at $30.42 per share plus 327,537 restricted stock units fully vested upon grant. The fully vested RSUs on day one is worth noting as a compensation structure detail.
She is presenting at the Jefferies Global Healthcare Conference on June 3. That is a reasonable institutional visibility event for a company this size.
The going concern language is still present in the filings. The post quarter financing helps substantially but it does not make that language disappear retroactively. Worth understanding rather than ignoring.
A lot of moving parts for a small company in a short window. The thesis hinges almost entirely on that China Phase 2 data in the second half of the year.
This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - [1](https://finance.yahoo.com/quote/CUE/), [2](https://www.cuebiopharma.com/), [3](https://stockresearchtoday.com/cue/)